Iconix Biosciences Inc. is pioneering the new field of chemogenomics, the integration of chemistry and genomics to profile drug candidates. Iconix’s chemogenomic capabilities enable pharmaceutical companies to increase the odds of advancing the right compounds to the clinic, reducing attrition rates and the costs of drug discovery. Iconix Biosciences is among the first of its kind: a multi-disciplinary company that integrates the laboratory skills and knowledge necessary for the creation of the world’s largest chemogenomics database of microarray and pharmacology data with the informatics expertise and computer skills required to mine and interpret this vast body of information. Iconix’s chemogenomics platform includes an integrated database architecture to bridge genomics and drug design, novel bio- and chemoinformatics software, and advanced expression array and cellular assay development capabilities. Iconix has focused these technologies on a line of chemogenomics products, services, and long-term collaborations.